DURHAM, N.C., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS ) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that Dr. Fred Miesowicz, the company's chief operating officer and vice president of manufacturing, will speak at the Phacilitate Cell & Gene Therapy Forum 2015 to be held January 26-28 th at the Grand Hyatt in Washington, D.C. Dr. Miesowicz is scheduled to present a case study during a focus session titled, "Logistics 1: Placing logistics at the heart of the cell and gene therapy business model," beginning at 2:30pm ET on January 26 th . He will also participate in a breakfast briefing titled, "Creating a cell therapy manufacturing system for commercial production," at 7:45am ET on January 27 th .
Dr. Miesowicz has served as Argos chief operating officer and vice president of manufacturing since February 2003. At Phacilitate he will discuss supply chain management, regulatory requirements, costs and logistical issues associated with cell therapy manufacturing systems for commercial production.
The Phacilitate Cell & Gene Therapy Forum is one of the largest cell and gene therapy business meetings with a focus on commercialization. Attendees will discuss clinical, regulatory and manufacturing issues that need to be addressed in order for cell and gene therapy companies to achieve commercial success.
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com .
Forward Looking Statements
Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtains approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent the Argos' views as of January 23, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to January 23, 2015.
Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: Nancy Yu Burns McClellan 212-213-0006
